<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606450</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-003</org_study_id>
    <nct_id>NCT00606450</nct_id>
  </id_info>
  <brief_title>Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis</brief_title>
  <acronym>PSOR-003</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-to-Severe Plaque-Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an unmet medical need for safe, effective oral therapy for moderate-to-severe
      psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The
      information obtained from the study will aid in the design of future clinical trials and to
      establish the safety and efficacy of CC-10004.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2006</start_date>
  <completion_date type="Actual">May 1, 2007</completion_date>
  <primary_completion_date type="Actual">February 1, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the clinical efficacy of 2 oral doses of CC-10004 with placebo when taken for 12 weeks in subjects with moderate-to-severe plaque-type psoriasis</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of CC-10004 compared with placebo in subjects with moderate-to-severe placque-type psoriasis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of CC-10004 compared to placebo on the quality of life in subjects with moderate-to-severe plaque-type psoriasis.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>20 mg Apremilast daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of CC-10004 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg Apremilast twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-10004 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-10004</intervention_name>
    <description>20 mg CC-10004 taken 1 time per day for 12 weeks</description>
    <arm_group_label>20 mg Apremilast daily</arm_group_label>
    <other_name>Apremilast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-10004</intervention_name>
    <description>20 mg of CC-10004 taken 2 times per day for 12 weeks</description>
    <arm_group_label>20mg Apremilast twice daily</arm_group_label>
    <other_name>Apremilast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo taken either 1 or 2 times per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must understand and voluntarily sign and informed consent form

          -  Must be in good health as judged by the investigator

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Must have greater than or equal to a 6 month history of moderate-to-severe plaque-type
             psoriasis

          -  Must have a Psoriasis Area and Severity Index (PASI) score greater than or equal to 10
             and Body Surface Area (BSA) greater than or equal to 10%

          -  Must meet specific laboratory criteria

          -  Must be a candidate for photo/systemic therapy

          -  Women of childbearing potential must have a negative pregnancy test

        Exclusion Criteria:

          -  Must not have clinically significant underlying disease processes

          -  Must not be pregnant or lactating females

          -  Must not have any condition, including lab abnormalities, which places the subject at
             unacceptable risk if the subject were to participate in the study or confounds the
             ability to interpret data from the study

          -  Must not have a history of active mycobacterium tuberculosis infection within 3 years
             prior to the screening visit

          -  Must not have a history of incompletely treated active of latent mycobacterium
             tuberculosis infection

          -  Must not have a know history of exposure to an infectious case of mycobacterium
             tuberculosis within 2 years prior to the screening visit

          -  Must not be an immigrant form a high-incidence country for mycobacterium tuberculosis
             disease within 2 years prior to the screening visit

          -  Must not have current erythrodermic, guttate, or pustular psoriasis

          -  Must not have a clinical history of failure to adequately respond to treatment in the
             investigator's opinion to one or more treatment courses of cyclosporine or the
             following biologic therapies: alefacept, etanercept, efalizumab, infliximab or
             adalimumab

          -  Must not use topical therapy within 14 days of randomization

          -  Must not use systemic therapy for psoriasis within 28 days of randomization

          -  Must not use phototherapy within 28 days of randomization

          -  Must not use adalimumab or infliximab within 3 months of randomization

          -  Must not use etanercept or efalizumab within 56 days of randomization

          -  Must not use alefacept within 6 months of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Stevens</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Dermatology and Cutaneous Science</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Dermatology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duronder C.P. Inc</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lynde Center for Dermatology</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 7N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>L3P 7N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Yves Poulin</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatovererology</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatovererology</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depart of Dermatology</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Ausburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatologie and Venerology</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology and Venerology</name>
      <address>
        <city>Frankfurt Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Herborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Salzwedel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celgene Clinical Site</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/clinical-study-report-csr-synopses/purposes-of-posting-clinical-study-report-csr-synopses</url>
    <description>Link to CSR synopsis</description>
  </link>
  <reference>
    <citation>Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3.</citation>
    <PMID>23030767</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2008</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

